"Lactams, Macrocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
LACTAMS forming compounds with a ring size of approximately 1-3 dozen atoms.
| Descriptor ID |
D047029
|
| MeSH Number(s) |
D02.065.589.327 D04.345.295
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lactams, Macrocyclic".
Below are MeSH descriptors whose meaning is more specific than "Lactams, Macrocyclic".
This graph shows the total number of publications written about "Lactams, Macrocyclic" by people in this website by year, and whether "Lactams, Macrocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2017 | 0 | 18 | 18 |
| 2018 | 2 | 20 | 22 |
| 2019 | 0 | 4 | 4 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Lactams, Macrocyclic" by people in Profiles.
-
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight. Biochem Biophys Res Commun. 2021 09 24; 571:26-31.
-
Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment. J Comput Chem. 2021 05 15; 42(13):897-907.
-
Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. Comb Chem High Throughput Screen. 2021; 24(5):716-728.
-
Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target. Emerg Microbes Infect. 2020 Dec; 9(1):2663-2672.
-
First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. Medicine (Baltimore). 2020 Nov 25; 99(48):e23357.
-
Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. SLAS Discov. 2020 12; 25(10):1097-1107.
-
Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Biosci Rep. 2020 06 26; 40(6).
-
A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol. 2020 11; 92(11):2631-2636.
-
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology. 2019 09; 70(3):771-787.
-
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019 09; 71(3):473-485.